Loading clinical trials...

Concurrent Use of Two Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes Mellitus (T1DM) | Clinical Trials | Clareo Health

COMPLETED

Concurrent Use of Two Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes Mellitus (T1DM)

Pilot Study of Concurrent Use of the SEVEN® and FreeStyle Navigator® Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes Mellitus

NCT00939289•DexCom, Inc.

View on ClinicalTrials.gov

Summary

The purpose of this pilot study is to evaluate performance of the SEVEN System and the Navigator System when both devices are worn concurrently by subjects with type 1 diabetes mellitus.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age 18 years or older;
•2. Have been diagnosed with type 1 diabetes and are on multiple daily injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) insulin therapy;
•3. Willing not to inject insulin or wear an insulin pump infusion set within 3 inches from either Sensor site;
•4. Willing to participate in an 8-hour in-clinic session on study Days 5, 10, and 15 and be willing to take 4 fingersticks per hour and have 4 blood draws per hour for the 8-hour duration of each of these in-clinic sessions;
•5. Willing to take a minimum of 6 fingersticks per day during home use;
•6. Willing to refrain from the use of acetaminophen during this study and for at least 24-hours prior to enrollment;
•7. Willing not to schedule an magnetic resonance (MRI) scan, computed tomography (CT) scan, x-ray, for the duration of the study;
•8. Able to speak, read, and write English.

Exclusion Criteria

•1. Have extensive skin changes/diseases that preclude wearing the Sensor on normal skin (e.g., extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos, dermatitis herpetiformis) at the proposed wear sites;
•2. Subjects who have a known allergy to medical-grade adhesives;
•3. Are pregnant as demonstrated by a positive pregnancy test within 72 hours of insertion;
•4. Have a hematocrit that is less than 30%, or greater than 55%;
•5. Current participation in another investigational study protocol (if a subject has recently completed participation in another drug study, the subject must have completed that study at least 30 days prior to being enrolled in this study);
•6. Have any condition that, in the opinion of the Investigator, would interfere with their participation in the trial or pose an excessive risk to study staff handling venous blood samples (e.g., known history of hepatitis B or C).

Locations (1)

Barbara Davis Center for Childhood Diabetes

Aurora, Colorado, United States

Key Dates

Start Date

July 1, 2008

Primary Completion Date

August 1, 2008

Completion Date

February 1, 2009

Last Updated

February 3, 2010

Enrollment

ACTUAL participants

Conditions

Type 1 Diabetes Mellitus

Interventions

Continuous Glucose Monitoring

DEVICE

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITINGNA

Implementing the Spotlight AQ Platform in Adolescent/ Young Adult (16-25 Years Old) Type 1 Diabetics (T1D)

NCT06390371

Type 1 Diabetes Mellitus

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 3, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Concurrent Use of Two Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes Mellitus (T1DM)

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Implementing the Spotlight AQ Platform in Adolescent/ Young Adult (16-25 Years Old) Type 1 Diabetics (T1D)

The Effects of Fluoxetine and/or DHEA

Fake Carbs Practice With AID System - MiniMed 780G in Children and Adolescents With T1D.

The COCCOS Study: a Transition Program for Young Persons With Chronic Conditions

Randomized Evaluation of Nonhealing Diabetic Foot Ulcers With Exclusive Wound Therapy